The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It’s free.
- New studies find that fluoride levels four to five times lower than those found in pregnant women in fluoridated communities cause IQ loss for the child, and that older women in fluoridated communities have a 50% higher risk of hip fractures.
- Plaintiffs suing the EPA in federal court over fluoridation’s neurotoxicity have continued to win legal victories and have shared deposition videos exposing CDC and EPA negligence.
- The former NTP director joined the chorus of scientific and public health experts raising alarms about neurotoxic risk, but the dental lobby responded by doubling their fluoridation expansion efforts.
A landmark study by Grandjean, et al., has been published confirming that very low levels of fluoride exposure during pregnancy impair the brain development of the child and at a population level may be causing more damage than lead, mercury or arsenic.
The study found that a maternal urine fluoride concentration of 0.2 mg/L, which is exceeded four to five times in pregnant women living in fluoridated communities, was enough to lower IQ by one point. The authors stated that even this impact is likely underestimated and:
“These findings provide additional evidence that fluoride is a developmental neurotoxicant … and the benchmark results should inspire a revision of water-fluoride recommendations aimed at protecting pregnant women and young children.”
A urinary fluoride (UF) concentration of 0.2 mg/L is far below what a pregnant woman in a fluoridated community would have, as confirmed by two recent studies.
A study of pregnant women in fluoridated San Francisco, California, found a mean UF concentration of 0.74 mg/L, and one with participants in fluoridated communities across Canada found a mean UF concentration of 1.06 mg/L. Both levels were significantly higher than those found in women in nonfluoridated communities.
Grandjean, et al.’s study, published in Risk Analysis, was a benchmark dose (BMD) analysis of the pooled data from the National Institutes of Health funded ELEMENT and MIREC birth cohorts in Mexico and Canada.